Zimmer Biomet Holdings, Inc. continued to defend its NexGen Flex knee product with another victory on Jan. 26, 2017 in a third bellwether case, Goldin v. Zimmer. After a four week trial, the jury in the U.S. District Court in the Northern District of Illinois rejected plaintiff's claim that Zimmer failed to warn of risks associated with use of the implant with obese patients.
Faegre Baker Daniels served as lead trial counsel for Zimmer in securing its third bellwether trial victory in defense of the company’s NexGen Flex knee product. This was especially noteworthy because the case was a “bellwether” trial selected to provide the Court and parties guidance for resolution of the MDL. It comes in conjunction with a similar trial win achieved by FaegreBD in the first bellwether trial, and the Court’s summary judgment ruling in favor of Zimmer in another bellwether matter. This is a significant victory for Zimmer in defending the NexGen Flex legacy of nearly 18 years of successfully treating millions of patients worldwide.